Literature DB >> 11874161

Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods?

Hannelore Götz1, Johan Lindback, Torvald Ripa, Malin Arneborn, Kristina Ramsted, Karl Ekdahl.   

Abstract

Based on clinical and laboratory surveillance data, trends in the incidence rates of genital Chlamydia trachomatis infections in Sweden between 1991 and 1999 were analysed according to age group and sex. The influence of changes in laboratory methods on the reported infections was assessed. After a decrease in the incidence rate of infection of 36% between 1991 and 1994, followed by a period of stability, a 20% increase was observed between 1997 and 1999 (from 157 to 189/100,000). Between 1991 and 1999 the female:male ratio decreased from 1.7 to 1.4. Incidence rates started to increase in 1994 in the 15-19 y age group for both sexes. Crude Chlamydia positivity increased from 4.1% (352,050 people tested) in 1994 to 5.4% (305,946 people tested) in 1999. This increase in Chlamydia positivity was seen both in laboratories that had changed to more sensitive methods and in those that had not. Changes in laboratory methods can therefore only partially explain the increase in notified cases. Increased screening of men may have contributed to the increase, but rising incidence rates in all young age groups of both sexes suggest a true increase in prevalence.

Entities:  

Mesh:

Year:  2002        PMID: 11874161     DOI: 10.1080/00365540110077001

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  36 in total

1.  Surveillance systems for STIs in the European Union: facing a changing epidemiology.

Authors:  C M Lowndes; K A Fenton
Journal:  Sex Transm Infect       Date:  2004-08       Impact factor: 3.519

2.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

3.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

4.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

5.  Characterization of the Horizontal and Vertical Sexual Transmission of Chlamydia Genital Infections in a New Mouse Model.

Authors:  Sukumar Pal; Delia F Tifrea; Luis M de la Maza
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

Review 6.  Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies.

Authors:  Byron E Batteiger; Fujie Xu; Robert E Johnson; Michael L Rekart
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

Review 7.  Development of a Chlamydia trachomatis T cell Vaccine.

Authors:  Karuna P Karunakaran; Hong Yu; Leonard J Foster; Robert C Brunham
Journal:  Hum Vaccin       Date:  2010-08-01

8.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling.

Authors:  David M Vickers; Nathaniel D Osgood
Journal:  BMC Infect Dis       Date:  2010-03-16       Impact factor: 3.090

10.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.